Cartesian Therapeutics, Inc. presented data from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG) at the 2024 MGFA Scientific Session of the AANEM Annual Meeting. The presentation highlighted positive topline results that were previously announced in July 2024, reinforcing the therapy's potential.
Descartes-08, the company's lead mRNA cell therapy candidate, has already received Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of MG. These designations underscore the significant unmet medical need and the innovative nature of Descartes-08.
The company confirmed its intention to hold an End-of-Phase 2 meeting with the FDA by the end of 2024 for Descartes-08. This meeting is crucial for reviewing the Phase 2b data and discussing the plans for initiating a pivotal Phase 3 clinical trial of Descartes-08 in MG, marking a key step towards potential market entry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.